Appeal 2007-1614
Application 09/779,447
and factional [sic] derivatives thereof is administered for a
period of time, subsequently the administration of the at least
one of tunicamycin and functional derivatives thereof is
suspended for a period of time of at least about 1 week, and
subsequently the administration of the at least one of
tunicamycin and functional derivatives thereof is resumed.
Thus, claim 9 is directed to a method of inhibiting angiogenesis, in a
patient in need of such treatment, by administering tunicamycin or a
functional derivative, suspending the treatment for at least one week, and
subsequently resuming the treatment.
2. PRIOR ART
The Examiner relies on the following references:
Dipak K. Banerjee et al., Is asparagine-linked protein glycosylation
an obligatory requirement for angiogenesis?, 30 Indian Journal of
Biochemistry and Biophysics 389-394 (December 1993).
Tony Tiganis et al., Functional and Morphological Changes Induced
by Tunicamycin in Dividing and Confluent Endothelial Cells, 198
Experimental Cell Research 191-200 (1992).
3. OBVIOUSNESS
Claims 9, 14, and 18 stand rejected under 35 U.S.C. § 103 as obvious
in view of Banerjee and Tiganis.
The Examiner cites Banerjee as “teach[ing] that the angiogenic
process of capillary endothelial cell proliferation is linked to the synthesis of
N-linked oligosaccharide chains which is inhibited by the pyrimidine
nucleoside tunicamycin” (Answer 3).1 The Examiner cites Tiganis as
“further support[ing] the recognition in the prior art of the inhibition of N-
1 Examiner’s Answer mailed September 29, 2006.
3
Page: Previous 1 2 3 4 5 6 7 8 Next
Last modified: September 9, 2013